APOL1-mediated kidney disease – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 02 Jun 2026 12:26:24 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png APOL1-mediated kidney disease – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of MZE829 capsules for adults with APOL1 kidney disease and protein in urine https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-mze829-for-adults-with-apol1-kidney-disease/ Wed, 29 Apr 2026 15:06:06 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-mze829-for-adults-with-apol1-kidney-disease/ This study focuses on APOL1 Kidney Disease (AKD), a specific type of chronic kidney disease that is linked to certain genetic variations. The investigational medication used in this study is called MZE829, which comes in the form of hard capsules that are taken by mouth.

The purpose of this research is to evaluate how safe and well-tolerated MZE829 is in adults who have kidney disease with high levels of protein in their urine (proteinuria) and carry specific high-risk genetic variations. This is a Phase 2 study, which means it follows initial safety testing of the medication in humans and aims to further understand how the treatment works in patients with the disease.

During the study, which lasts up to 84 days, participants will take MZE829 capsules. Throughout this period, various health assessments will be performed, including monitoring of side effects, vital sign measurements, laboratory tests, and heart rhythm recordings. These assessments help determine how safe the medication is and how well patients tolerate it.

]]>